|
Age*
|
48 (40–54)
|
48 (43–53)
|
51 (43–57)
|
0.008
|
|
Male sex
|
126 (74.1)
|
95 (67.4)
|
127 (69.4)
|
0.399
|
|
Caucasians
|
157 (92.4)
|
136 (96.5)
|
164 (89.6)
|
0.165
|
|
HIV risk factor
|
0.043
|
|
Heterosexual
|
74 (43.5)
|
68 (48.2)
|
83 (45.4)
| |
|
MSM
|
84 (49.4)
|
49 (34.8)
|
80 (43.7)
| |
|
IDUs
|
11 (6.5)
|
24 (17.0)
|
19 (10.4)
| |
|
Other
|
1 (0.6)
|
0
|
1 (0.5)
| |
|
CDC stage C
|
48 (28.2)
|
34 (24.1)
|
53 (29.0)
|
0.592
|
|
HCV positive serostatus
|
18 (10.6)
|
25 (17.7)
|
26 (14.2)
|
0.193
|
|
Nadir CD4 count (cells/μL)*
|
219 (64–311)
|
194 (62–293)
|
194 (64–284)
|
0.741
|
|
Zenith HIV-RNA (log10 copies/mL)*
|
4.90 (4.36–5.40)
|
5.02 (4.48–5.39)
|
4.93 (4.34–5.40)
|
0.687
|
|
CD4 count at baseline (cells/μL)*
|
617 (484–793)
|
616 (509–786)
|
630 (500–800)
|
0.671
|
|
Years since HIV diagnosis*
|
9 (5–17)
|
11 (4–18)
|
14 (8–20)
|
< 0.001
|
|
Years on antiretroviral therapy*
|
8 (3–14)
|
7 (3–13)
|
12 (5–18)
|
< 0.001
|
|
Previous virological failure
|
91 (53.5)
|
78 (55.3)
|
94 (51.4)
|
0.775
|
|
Previous M184 V resistance mutation
|
22 (12.9)
|
17 (12.1)
|
16 (8.7)
|
0.419
|
|
Years of viral suppression at baseline*
|
5 (2–8)
|
4 (2–7)
|
8 (4–11)
|
< 0.001
|
|
Previous regimen:
|
< 0.001
|
|
2NRTI + bPI
|
80 (47.1)
|
125 (88.7)
|
14 (7.7)
|
|
2NRTI + NNRTI
|
20 (11.8)
|
4 (2.8)
|
34 (18.6)
|
|
2NRTI + INI
|
24 (14.1)
|
1 (0.7)
|
32 (17.5)
|
|
Two-drug regimen
|
34 (20.0)
|
8 (5.7)
|
99 (54.1)
|
|
- Lamivudine plus bPI
|
32 (18.8)
|
8 (5.7)
|
89 (48.6)
|
|
- bPI plus NNRTI, InSTI or MVC
|
2 (1.2)
|
0 (0)
|
6 (3.3)
|
|
- Other regimen
|
0 (0)
|
0 (0)
|
4 (2.2)
|
|
Other
|
12 (7.1)
|
3 (2.1)
|
4 (2.2)
|
|
TDF in previous regimen
|
97 (57.1)
|
119 (84.4)
|
65 (35.5)
|
< 0.001
|
|
Reasons for switch to dual regimen:
|
< 0.001
|
|
Simplification
|
86 (50.6)
|
100 (70.9)
|
57 (31.1)
|
|
Dyslipidemia
|
8 (4.7)
|
7 (5.0)
|
60 (32.8)
|
|
GI toxicity
|
4 (2.4)
|
2 (1.4)
|
13 (7.1)
|
|
Liver toxicity
|
11 (6.5)
|
0
|
4 (2.2)
|
|
Renal toxicity
|
28 (16.5)
|
12 (8.5)
|
15 (8.2)
|
|
Bone toxicity
|
3 (1.8)
|
3 (2.1)
|
12 (6.6)
|
|
CNS toxicity
|
1 (0.6)
|
0
|
3 (1.6)
|
|
Other toxicity
|
14 (8.2)
|
4 (2.8)
|
7 (3.8)
|
|
DDI
|
2 (1.2)
|
0
|
6 (3.3)
|
|
Other
|
13 (7.6)
|
13 (9.2)
|
6 (3.3)
|
|
Years on previous regimen*
|
2 (1–4)
|
3 (1–5)
|
2 (1–3)
|
0.530
|
|
Study period:
|
< 0.001
|
|
2008–2013
|
37 (21.8)
|
88 (62.4)
|
0
|
|
2013–2014
|
91 (53.5)
|
33 (23.4)
|
0
|
|
2014–2015
|
34 (20.0)
|
12 (8.5)
|
77 (42.1)
|
|
2015–2017
|
8 (4.7)
|
8 (5.7)
|
106 (57.9)
|
